Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program on July 28, 2026 anti-TSHR centanafadine Drug Enforcement Administration NDSRI Otsuka reverse merger SIMTRIYO Thyroid associated opthalmopathies United States Food and Drug Administration Vyne yarrow flower extract YARW YB-101 +
FDA Approves Otsuka's Tool SIMTRIYO on July 27, 2026 Approved Attention deficit hyperactivity disorder centanafadine Clinical Nurse Specialists Drug Enforcement Administration NDSRI Otsuka SIMTRIYO Stimulant United States Food and Drug Administration +
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears – 2026 analysis on June 26, 2026 Anxiety Attention deficit hyperactivity disorder centanafadine Otsuka PDUFA United States Food and Drug Administration +